Barry Hafkin
Technik-/Wissenschafts-/F&E-Leiter bei MicuRx Pharmaceuticals, Inc.
Profil
Barry Hafkin is currently the Chief Medical Officer & Executive Vice President at MicuRx Pharmaceuticals, Inc. He previously worked as the Chief Scientific Officer at Middlebrook Pharmaceuticals, Inc. and as the Chief Medical Officer at Affinium Pharmaceuticals Ltd.
Hafkin holds a doctorate degree from The University of Texas at Austin and an undergraduate degree from the University of Houston.
Aktive Positionen von Barry Hafkin
| Unternehmen | Position | Beginn |
|---|---|---|
MicuRx Pharmaceuticals, Inc.
 MicuRx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology MicuRx Pharmaceuticals, Inc. is a holding company, which engages in the discovery, development, and commercialization of safe and effective antimicrobial therapeutics for multidrug-resistant superbag infections. The company was founded by Zheng Yu Yuan and Mikhail Fedorovich Gordeev in March 2007 and is headquartered in Pudong, China. | Technik-/Wissenschafts-/F&E-Leiter | 02.11.2015 |
Ehemalige bekannte Positionen von Barry Hafkin
| Unternehmen | Position | Ende |
|---|---|---|
Affinium Pharmaceuticals Ltd.
 Affinium Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Affinium Pharmaceuticals Ltd. is a holding company, which engages in the provision of clinical development of antibacterial. It specializes in hte development of antibiotics that targets the bacterial fatty acid synthesis pathway. It focuses on small molecule antibacterials targeting FabI, an essential enzyme in the bacterial fatty acid cycle. The company was founded in 2000 and is headquartered in Austin, TX. | Technik-/Wissenschafts-/F&E-Leiter | - |
Middlebrook Pharmaceuticals, Inc.
 Middlebrook Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology MiddleBrook Pharmaceuticals, Inc. develops and commercializes anti-infective drug products. It operates mainly in prescription pharmaceuticals. MiddleBrook's main product is PULSYS. PULSYS technology offers the prolonged release and absorption of a drug. The company was incorporated in December 1999 and is headquartered in Westlake, TX. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Barry Hafkin
| The University of Texas at Austin | Doctorate Degree |
| University of Houston | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Middlebrook Pharmaceuticals, Inc.
Middlebrook Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology MiddleBrook Pharmaceuticals, Inc. develops and commercializes anti-infective drug products. It operates mainly in prescription pharmaceuticals. MiddleBrook's main product is PULSYS. PULSYS technology offers the prolonged release and absorption of a drug. The company was incorporated in December 1999 and is headquartered in Westlake, TX. | Health Technology |
Affinium Pharmaceuticals Ltd.
Affinium Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Affinium Pharmaceuticals Ltd. is a holding company, which engages in the provision of clinical development of antibacterial. It specializes in hte development of antibiotics that targets the bacterial fatty acid synthesis pathway. It focuses on small molecule antibacterials targeting FabI, an essential enzyme in the bacterial fatty acid cycle. The company was founded in 2000 and is headquartered in Austin, TX. | Health Technology |
MicuRx Pharmaceuticals, Inc.
MicuRx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology MicuRx Pharmaceuticals, Inc. is a holding company, which engages in the discovery, development, and commercialization of safe and effective antimicrobial therapeutics for multidrug-resistant superbag infections. The company was founded by Zheng Yu Yuan and Mikhail Fedorovich Gordeev in March 2007 and is headquartered in Pudong, China. | Health Technology |
